Merus B.V.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Merus B.V. sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Merus B.V.: 8 sponsored US clinical trials, 4 recruiting.
Merus B.V. sponsors 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 2 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Head and Neck Squamous Cell Carcinoma, with 4 trials.
Upper-quartile sponsor footprint
Merus B.V. sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
NCT07353957
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
NCT06496178
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
NCT04868877
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies
NCT03922204
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
NCT03321981
MCLA-117 in Acute Myelogenous Leukemia
NCT03038230
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Merus B.V. pipeline
4 recruiting of 8 indexed (50% open); 2 completed (25%).
Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Head and Neck Squamous Cell Carcinoma (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Merus B.V.: open-pipeline peers nationwide
Peers matched on 8 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Merus B.V. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
Related
What to do with this Merus B.V. page
8 registered trials is a research-attention snapshot, not an endorsement of Merus B.V. or any single study.
- 4 of Merus B.V.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Head and Neck Squamous Cell Carcinoma is the condition Merus B.V. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Head and Neck Squamous Cell Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Merus B.V. pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.